KaloBios Pharma (KBIO) Announces Filing of 10-Q, 10-K for 2015

September 2, 2016 7:31 AM EDT
Get Alerts KBIOQ Hot Sheet
Price: $4.25 -7.41%

Today's EPS Names:
Trade KBIOQ Now!
Join SI Premium – FREE

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

KaloBios Pharmaceuticals, Inc. (OTC: KBIO) announced the filing with the U.S. Securities and Exchange Commission (SEC) of the company’s Form 10-Q for the three and nine months ended September 30, 2015, and its Form 10-K for the fiscal year ended December 31, 2015.

The filings mark an important step towards the achievement of one of the company’s key near-term goals of regaining compliance with periodic reporting requirements of the SEC and to seek relisting on a national securities exchange.

“Our momentum continues to build due to our intense focus on executing our strategic priorities,” said Cameron Durrant, MD, KaloBios chairman and CEO. “We intend to be back in compliance with our filings as expeditiously as possible, as we also work to strengthen our financial position and accelerate our pipeline programs.”

KaloBios emerged from bankruptcy on June 30, 2016, with new management and a transformational strategy, including the Responsible Pricing Model.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Earnings

Related Entities


Add Your Comment